NYLI U.S. Large Cap R&D Leaders ETF (LRND)

The NYLI U.S. Large Cap R&D Leaders ETF (ticker: LRND) is an exchange-traded fund that selects and weights large-capitalization U.S. companies based on the intensity of their research and development spending — that is, how much they invest in R&D as a proportion of total revenue. The fund uses this metric as a proxy for innovation capacity and long-term competitive strength, betting that companies willing to spend heavily on future products and capabilities tend to generate superior returns.

What LRND tracks and why

LRND is built on a specific thesis: that companies which invest the most in research and development, relative to the revenue they generate today, tend to possess durable competitive advantages and be willing to sacrifice near-term profits for long-term market share. The fund selects from the universe of large-cap U.S. stocks — firms typically with market capitalizations in the billions — and then weights its holdings based on trailing research and development expenditure as a percentage of sales.

This means the fund is tilted toward certain sectors almost by design. Technology companies, pharmaceuticals and biotechnology, and industrial manufacturers with heavy engineering costs tend to appear overweighted, because these industries simply spend more on R&D as a matter of business model. A software company that invests forty percent of revenue into engineering and product teams will rank higher in the fund than a utilities company that invests one percent, even if both are profitable and well-managed. LRND is therefore not a broadly representative index of the largest U.S. firms; it is a thematic fund with a deliberate tilt.

The rationale rests on the idea that R&D spending reveals management’s true priorities and confidence in the future. When a company commits substantial capital to research that may not pay off for years, it signals both the belief that the investment is worth making and the competitive moat strong enough to justify the expense. This contrasts with a mature commodity business where R&D adds little value and so is minimized. By weight, LRND holds companies that have chosen to compete on innovation rather than cost-cutting.

Structure, costs, and how it trades

LRND is a conventional exchange-traded fund — not a leveraged product, not an inverse product, not a structured note. It trades during market hours on a stock exchange like any other security, with a fund symbol you can buy and sell through a standard brokerage account. The liquidity depends on the size and popularity of the fund; broadly, larger and more-established ETFs tend to have tighter bid-ask spreads, while newer or smaller funds may require a wider margin to fill a trade.

The fund carries an expense ratio that covers the costs of running the fund — management fees, data licensing for the R&D metrics, trading to maintain the holdings, and administrative overhead. That ratio is one of the few publicly disclosed costs and is a reasonable way to compare the fund to competitors. Beyond the expense ratio, investors encounter transaction costs when buying or selling (the bid-ask spread) and tax consequences if they hold the fund in a taxable account, since rebalancing or holdings turnover can trigger capital gains.

LRND rebalances periodically — typically quarterly or annually, though the exact schedule varies by fund policy — to maintain the weighting scheme and to incorporate updated R&D spending figures. That rebalancing can generate some turnover, and higher turnover typically means higher trading costs and more tax-generating events.

Who this fund is for

LRND is most relevant to investors who believe that R&D spending is a reliable signal of competitive advantage and future returns, and who want to build a concentrated bet on that theme without picking individual stocks. The fund appeals to those who think the technology and innovation-driven sectors will outperform and who prefer owning a broad basket of the most R&D-intensive names rather than betting on a single company.

Because LRND overweights technology and related sectors, it carries sector concentration risk — if those industries underperform, the fund likely underperforms broadly. It is also best suited to longer-term holders, since the daily volatility of growth-heavy stocks and the effects of rebalancing may detract from shorter-term returns. An investor with a low tolerance for drawdowns or who needs the money within a few years should be cautious.

Research and due diligence

Anyone considering LRND should start with the fund’s prospectus and fact sheet, which detail the exact methodology for R&D calculation, the rebalancing schedule, the list of current holdings, and the expense ratio. These documents lay out what the fund is actually tracking and owning, and they clarify any index definitions. Morningstar and similar fund research sites publish independent analysis of the fund’s performance, peer comparison, and historical tracking error.

An investor should also look at the underlying index definition — what companies qualify, how R&D spending is measured, and how it is weighted. R&D can be reported differently across companies (some expense it, some capitalize and amortize), so understanding the fund’s methodology matters. Finally, comparing LRND to other large-cap growth or innovation-themed ETFs clarifies whether this specific angle on R&D intensity offers better risk-adjusted returns or simply reflects a different flavor of sector concentration. Index and fund fact sheets are the primary sources here, along with performance data from the fund sponsor and independent mutual-fund tracking platforms.